Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
Phase: PHASE2
Conditions: Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
Sponsor: Washington University School of Medicine

 
 
 
 
 
 
______________________________________________________________________________________ 
 
1 
 
 
 
Baricitinib for the Treatment  
of Ocular Mucous Membrane Pemphigoid 
 
 
Principal Investigator:   
Michael A. Paley, M.D., Ph.D. 
 
IND #: 154922 
 
 
 
 
Version Date: June 30, 2021 
Version Number:  1 
 
 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
2 
TABLE OF CONTENTS 
 
A 
INTRODUCTION ................................................................................................................................................5 
A1 
STUDY ABSTRACT ..........................................................................................................................................5 
A2 
PRIMARY HYPOTHESIS ...................................................................................................................................5 
A3 
PURPOSE OF THE STUDY PROTOCOL ..............................................................................................................5 
B 
BACKGROUND ..................................................................................................................................................5 
B1 
PRIOR LITERATURE AND STUDIES ..................................................................................................................5 
B2 
RATIONALE FOR THIS STUDY .........................................................................................................................6 
C 
STUDY OBJECTIVES ........................................................................................................................................6 
C1 
PRIMARY AIM ................................................................................................................................................6 
C2 
SECONDARY AIMS ..........................................................................................................................................7 
C3 
EXPLORATORY ANALYSIS ..............................................................................................................................7 
C4 
PRECLINICAL DATA .......................................................................................................................................7 
C5 
CLINICAL DATA TO DATE ..............................................................................................................................7 
C6 
DOSE RATIONALE AND RISK/BENEFITS .........................................................................................................8 
D 
STUDY DESIGN ..................................................................................................................................................8 
D1 
OVERVIEW OR DESIGN SUMMARY .................................................................................................................8 
D2 
SUBJECT SELECTION AND WITHDRAWAL .......................................................................................................9 
2.a 
Inclusion Criteria ......................................................................................................................................9 
2.a 
Exclusion Criteria ...................................................................................................................................10 
2.b 
Ethical Considerations............................................................................................................................13 
2.c 
Subject Recruitment Plans and Consent Process ...................................................................................14 
2.d 
Randomization Method and Blinding .....................................................................................................14 
2.e 
Risks and Benefits ...................................................................................................................................14 
2.f 
Early Withdrawal of Subjects ......................................................................................................................15 
2.g 
When and How to Withdraw Subjects .....................................................................................................15 
2.h 
Data Collection and Follow-up for Withdrawn Subjects .......................................................................15 
2.i 
Temporary Discontinuation of Therapy ......................................................................................................15 
i 
Indications for temporary discontinuation of therapy ........................................................................................ 15 
ii 
Monitoring after temporary discontinuation of therapy ..................................................................................... 15 
iii 
Reinitiation of therapy ............................................................................................................................................ 16 
2.j 
Permanent Discontinuation of Therapy ......................................................................................................16 
i 
Indications for cessation of therapy ..................................................................................................................... 16 
ii 
Monitoring after treatment cessation ................................................................................................................... 17 
2.k 
Adjustment of therapy .............................................................................................................................17 
Indications for adjustment of therapy ............................................................................................................................ 17 
Adjustment therapy .......................................................................................................................................................... 17 
D3 
STUDY DRUG ...............................................................................................................................................17 
3.a 
Description ..............................................................................................................................................17 
3.b 
Treatment Regimen .................................................................................................................................17 
3.c 
Method for Assigning Subjects to Treatment Groups .............................................................................17 
3.d 
Preparation and Administration of Study Drug......................................................................................17 
3.e 
Subject Compliance Monitoring .............................................................................................................17 
3.f 
Prior and Concomitant Therapy .................................................................................................................18 
3.g 
Packaging ...............................................................................................................................................18 
3.h 
Masking of Study Drug ...........................................................................................................................18 
3.i 
Receiving, Storage, Dispensing and Return ................................................................................................18 
E 
STUDY PROCEDURES ....................................................................................................................................19 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
3 
E1 
SCREENING FOR ELIGIBILITY .......................................................................................................................19 
E2 
MEASUREMENTS ..........................................................................................................................................19 
E3 
SCHEDULE OF MEASUREMENTS ...................................................................................................................19 
E4 
INITIAL VISIT (WEEK 0; SCREENING) ...........................................................................................................19 
E5 
BASELINE VISIT (WEEK 1) ...........................................................................................................................20 
E6 
SUBSEQUENT VISIT (WEEK 5) ......................................................................................................................20 
E7 
SUBSEQUENT VISIT (WEEK 9) ......................................................................................................................20 
E8 
OPEN-LABEL EXTENSION .............................................................................................................................21 
E9 
E-MAIL AND TEXT MESSAGE COMMUNICATION ..........................................................................................21 
E10 
SAFETY AND ADVERSE EVENTS ...................................................................................................................21 
10.a 
Safety and Compliance Monitoring ........................................................................................................21 
10.b 
Medical Monitoring ................................................................................................................................21 
i 
Data Safety Monitoring .......................................................................................................................................... 21 
ii 
Hepatitis B Virus DNA Monitoring ....................................................................................................................... 22 
10.c 
Definitions of Adverse Events (AEs) .......................................................................................................22 
10.d 
Definition of Serious Adverse Events (SAEs) ..........................................................................................22 
10.e 
Pregnancy ...............................................................................................................................................22 
10.f 
Classification of Events ...........................................................................................................................23 
i 
Relationship ............................................................................................................................................................ 23 
ii 
Severity .................................................................................................................................................................... 23 
iii 
Expectedness ......................................................................................................................................................... 23 
10.g 
Data Collection Procedures for Adverse Events ....................................................................................23 
10.h 
Reporting Procedures .............................................................................................................................23 
10.i 
Serious Adverse Event Reporting Period ................................................................................................24 
10.j 
Post-study Adverse Event ........................................................................................................................24 
E11 
STUDY OUTCOME MEASUREMENTS AND ASCERTAINMENT .........................................................................24 
F 
STATISTICAL PLAN .......................................................................................................................................24 
F1 
SAMPLE SIZE DETERMINATION AND POWER ....................................................................................................24 
F2 
INTERIM MONITORING AND EARLY STOPPING .................................................................................................25 
F3 
ANALYSIS PLAN ...............................................................................................................................................25 
F4 
STATISTICAL METHODS ....................................................................................................................................25 
F5 
MISSING OUTCOME DATA ................................................................................................................................25 
F6 
UNMASKING PROCEDURES ...............................................................................................................................25 
G 
DATA HANDLING AND RECORD KEEPING ............................................................................................25 
G1 
CONFIDENTIALITY AND SECURITY ...............................................................................................................25 
G2 
TRAINING .....................................................................................................................................................26 
G3 
RECORDS RETENTION ..................................................................................................................................26 
H 
STUDY MONITORING, AUDITING, AND INSPECTING .........................................................................26 
H1 
STUDY MONITORING PLAN ..........................................................................................................................26 
H2 
AUDITING AND INSPECTING .........................................................................................................................26 
2.a 
Audits ......................................................................................................................................................26 
2.b 
Inspections ..............................................................................................................................................26 
I 
STUDY ADMINISTRATION ...........................................................................................................................26 
I1 
ORGANIZATION AND PARTICIPATING CENTERS ................................................................................................26 
I2 
FUNDING SOURCE AND CONFLICTS OF INTEREST .............................................................................................27 
I3 
SUBJECT STIPENDS OR PAYMENTS ...................................................................................................................27 
I4 
STUDY TIMETABLE ...........................................................................................................................................27 
J 
PUBLICATION PLAN ......................................................................................................................................27 
K 
ATTACHMENTS ..............................................................................................................................................28 
K1 
TABLES ........................................................................................................................................................28 
K2 
INFORMED CONSENT DOCUMENTS ................................................................................................................30 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
4 
K3 
QUESTIONNAIRES OR SURVEYS ....................................................................................................................30 
L 
REFERENCES ...................................................................................................................................................30 
 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
5 
 
A Introduction 
 
A1 Study Abstract 
Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that 
can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence 
of 1 in 60,000. There are currently no FDA-approved medications for the treatment of mucous 
membrane pemphigoid, highlighting a clear unmet need. 
 
At present, moderate to severe disease requires off-label use of potent immunosuppressive 
agents, such as oral anti-proliferatives (methotrexate, azathioprine, and mycophenolate), 
rituximab (RTX) or cyclophosphamide (CyC). Recently, Janus kinase (JAK) inhibition with 
baricitinib been reported to be successful in one case of ocular MMP. In addition, we have had 
success with JAK inhibition in 2 cases of ocular MMP after failure of RTX and CyC. 
 
We propose a randomized, single-masked, two-arm study of baricitinib vs anti-proliferatives in 
20 patients with ocular MMP.  
A2 Primary Hypothesis 
Baricitinib is efficacious in the treatment of ocular mucous membrane pemphigoid. 
A3 Purpose of the Study Protocol 
To conduct a pilot, single-masked, randomized trial comparing the efficacy of baricitinib vs. 
standard therapy with anti-proliferative to reduce disease activity in patients diagnosed with 
ocular mucous membrane pemphigoid. 
  
B Background 
 
B1 Prior Literature and Studies 
MMP is a chronic, autoimmune disease that affects the mucosal membranes leading to oral, 
nasal, laryngeal, esophageal, and genital ulcers as well as a cicatrizing (scarring) conjunctivitis 
of the eyes. This process is thought to be due to auto-antibodies that bind the a6b4 integrin of 
the basement membrane. Auto-antibody binding activates complement and drives immune cell 
infiltration into, and ultimately destruction of, conjunctival membranes. Incomplete control of the 
disease generally leads to a slow but progressive fibrotic process of the conjunctiva over 
months to years that can progress to severe vision loss and blindness. Ocular MMP affects 
approximately 1 in 60,000 individuals (1) and has no FDA-approved medical therapies. Patients 
are often treated with off-label use of a variety of immunosuppressants, including steroids, 
methotrexate, 
azathioprine, 
mycophenolate, 
rituximab, 
cyclophosphamide, 
intravenous 
immunoglobulin (IVIg), and anti-tumor necrosis factor (TNF) agents. 
 
 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
6 
In the Washington University Ocular Inflammation Clinic, patients with ocular MMP are treated 
collaboratively by ophthalmologists (Drs. Huang and Margolis) and rheumatologists (Dr. Paley 
and colleagues). We have successfully treated two patients with ocular MMP with a JAK 
inhibitor (tofacitinib) after both had failed multiple other therapies: methotrexate, mycophenolate, 
rituximab, and cyclophosphamide as well as IVIg in one patient. Both patients showed an 
improvement in disease activity by 8 weeks of therapy with tofacitinib. The choice to initiate JAK 
inhibition was spurred by the prior publication of successful use of baricitinib in a patient with 
ocular MMP who had failed methotrexate, mycophenolate, rituximab, cyclophosphamide, IVIg, 
and adalimumab (2). Similar to what was observed in our two patients, the report noted 
improvement at 8 weeks of therapy with baricitinib. 
B2 Rationale for this Study 
 
Aside from the published case report and our own experience with refractory ocular MMP that 
responded to JAK inhibition, there are other reasons to think that baricitinib may be an effective 
agent in ocular inflammatory disease. Baricitinib is an orally available small molecule JAK 
inhibitor that is used to treat moderate to severe rheumatoid arthritis. Several inflammatory 
cytokines that activate JAK/STAT signaling have also been implicated in the pathogenesis of 
ocular MMP. For example, in conjunctival biopsies, the interleukins IL-6, IL-12, and IL-13 are 
upregulated in ocular MMP compared to healthy controls (3, 4). In the conjunctiva, IL-13 is 
produced by infiltrating T cells and acts as a chemoattractant for fibroblasts (4), likely 
contributing to the fibrotic phase of the disease. In a contemporaneous process, IL-6 is a 
pleiotropic cytokine that facilitates the recruitment of immune cells to inflamed tissues (5) and 
promotes their proliferation and differentiation (6-8). Of particular importance to ocular MMP, IL-
6 is a growth factor for plasmablasts, which have been implicated as a source of auto-antibody 
production in several autoimmune diseases (9-11). As a result, baricitinib blocks multiple pro-
inflammatory cytokines involved in the pathogenesis of ocular MMP. 
 
C Study Objectives 
 
C1 Primary Aim 
Note: The outcomes for each eye eligible for the study will be assessed independently. See 
Table 1 for measurement frequency and evaluator. 
 
Primary Endpoint:  
• 
Treatment response of ocular inflammation based on conjunctival injection measured by 
ophthalmologic exam of the palpebral conjunctiva. This quantitative measurement is 
adapted from Munyangango et al. (12):  Each eye is divided into quadrants and each 
quadrant is scored as listed below with the total sum being the sum of all 4 quadrants for 
a total score of 0-12 for each eye. A clinically meaningful response will be defined as a 
≥30% reduction in the score for the eye. 
o 0 (white and quiet) 
o 1 (mild) 
o 2 (moderate) 
o 3 (severe) 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
7 
C2 Secondary Aims 
• 
A decrease of ocular inflammation to 0 for the eye (based on the primary endpoint score) 
o Only evaluated if primary endpoint is reached 
• 
Change in best-corrected or pinhole distance visual acuity 
o Clinically meaningful improvement or worsening will be defined as a change in 10 
letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale 
• 
Change in Fibrosis 
o e.g. symblepharon, fornix shortening, ankyloblepharon, entropion, trichiasis 
o Based on Tauber grade: each eye is scored 1-5 and sum is divided by 10. 
o Improvement or worsening will be defined by a change of 0.1 on 0.2 - 1 scale. 
• 
Development of corneal involvement  
o Defined as interval development of punctate corneal epithelial keratitis, corneal 
epithelial defects, or conjunctivalization of the cornea  
o This will be assessed as present or absent 
• 
Therapeutic response of extra-ocular manifestations, when applicable and available 
o See Table 2 below 
C3 Exploratory Analysis 
• 
Treatment response of ocular inflammation based on conjunctiva photography 
o Scored using the same scale as the primary endpoint 
o With and without a red free filter  
§ 
Which offers clearer delineation of fibrosis and blood vessels 
• 
Biospecimens such as blood and impression cytology of the ocular surface will be 
collected for identification of biomarkers. The biomarker testing may include, but is not 
limited to, RNA sequencing.  
• 
Patient Reported Outcomes (PROs) will be measured by the National Eye Institute 
Visual Function Questionnaire-25 (NEI VFQ-25) and Skindex-16 
C4 Preclinical Data 
Baricitinib is a small molecule that reversibly inhibits Janus associated kinases (JAKs) with 
some selectivity for JAK1 and JAK2. JAKs execute cytokine receptor signaling by 
phosphorylation and activation of signal transducers and activator of transcription (STAT) 
proteins, which subsequently dimerize, enter the cell nucleus, and initiate transcription of 
numerous inflammatory genes. Topical administration of the JAK inhibitor tofacitinib has 
demonstrated efficacy in treating ocular inflammation in animal models (13, 14) and humans 
(15, 16). 
 
There are no preclinical models of ocular mucous membrane pemphigoid. 
C5 Clinical Data to Date  
JAK inhibition with baricitinib has been successful in the treatment of ocular MMP for one 
patient who had failed methotrexate, mycophenolate, rituximab, cyclophosphamide, IVIg, and 
adalimumab (2). This report noted improvement at 8 weeks of therapy with baricitinib. Similarly, 
we have successfully treated two patients with ocular MMP with a JAK inhibitor (tofacitinib) after 
both had failed multiple other therapies: methotrexate, mycophenolate, rituximab, and 
cyclophosphamide as well as IVIg in one patient (James H et al., in preparation). Both patients 
showed an improvement in disease activity by 8 weeks of therapy with tofacitinib. Collectively, 
these cases suggest clinical efficacy of JAK inhibitors in the treatment of ocular MMP. 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
8 
 
Baricitinib is an FDA-approved medication for the treatment of rheumatoid arthritis. Treatment 
with baricitinib leads to a clinical response starting 2-8 weeks after initiation of therapy (17). 
Administration of baricitinib is approved for 2mg daily for rheumatoid arthritis, however, the 4mg 
daily dose has demonstrated greater clinical efficacy (18). 
C6 Dose Rationale and Risk/Benefits  
Ocular MMP is a vision-threatening disease that risks permanent disability if left uncontrolled. 
This protocol is designed to demonstrate proof of concept that baricitinib is efficacious for ocular 
MMP. The 4mg dose of baricitinib was selected for several reasons. First, this was the dose 
used in prior publication of efficacy for the treatment of ocular MMP (2). Second, the 4mg dose 
of baricitinib is superior to the 2mg dose in the treatment of inflammatory disease such as 
rheumatoid arthritis (17). Third, the 4mg dose has a similar safety profile to anti-TNF agents 
(18), which are used off-label to treat ocular MMP. Thus, the 4mg dose was chosen to maximize 
the potential for efficacy while maintaining a similar risk profile to alternative off-label therapies. 
D Study Design  
 
D1 Overview or Design Summary 
Since the safety profile of baricitinib is well established, we propose a pilot randomized trial 
focused on efficacy of baricitinib monotherapy compared to standard anti-proliferative 
monotherapy in the reduction of disease activity in ocular MMP.  
 
Subjects with active ocular MMP based on ophthalmologic exam will be enrolled (19). Patients 
will be evaluated for eligibility criteria and enrolled at a screening visit (week 0). To minimize 
confounding contributors to active disease such as dry eye, trichiasis (trauma to ocular surface 
from inward turned eyelashes), and subclinical infection, patients will be treated empirically with 
lubricating drops (daytime) and ointment (night time), trichiatic eyelash removal, and antibiotic 
drops for 1 week prior to their baseline exam. This week of ocular surface optimization will also 
serve as a washout period for previous topical therapy. Patients will initiate therapy (baricitinib 
or anti-proliferative) after the baseline exam at week 1. Patients will be evaluated for disease 
activity at weeks 1 (baseline), 5 and 9. The evaluating cornea specialist will be masked with 
respect to the treatment arms.  Our primary endpoint will be evaluated at week 9 (8 weeks of 
therapy) based on (a) the rate of response to JAK inhibition in our 2 previous patients, (b) rate of 
response to baricitinib in a prior report (one case) (2), and (c) the rapid clinical effect of JAK 
inhibition in other autoimmune diseases. The primary objective is to estimate clinical response 
in the baricitinib group compared to standard of care. 
 
Patients will be treated with monotherapy in both study arms for weeks 1 through 9. After week 
9, patients will have the opportunity to transition to an open-label extension of baricitinib 4mg 
daily for a period of 104 weeks. Combination therapy with anti-proliferatives (methotrexate, 
azathioprine, mycophenolate) will be allowed during the open label extension for active disease 
at or after week 9. Changes to anti-proliferatives are not allowed during week 0 through week 9, 
but are allowed during the open label extension. Steroids will not be used as this is not a part of 
our practice pattern at Washington University. 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
9 
D2 Subject Selection and Withdrawal  
2.a 
Inclusion Criteria  
Patients are eligible to be included in the study only if they meet all the following criteria: 
 
Type of Patient and Disease Characteristics 
1. Are at least 18 years of age  
2. Have a clinical diagnosis of Ocular Mucous Membrane Pemphigoid 
a. The treating ophthalmologist will have excluded alternative etiologies that can cause 
cicatrizing conjunctivitis such as: 
o Rosacea 
o Atopic dermatitis 
o Lichen Planus 
o Iatrogenic interventions, e.g. glaucoma eye drops 
o Stevens-Johnsons Syndrome 
o Graft vs Host Disease 
3. Have active disease based on ophthalmologic exam 
 
Patient Characteristics 
4. Nonpregnant, nonbreastfeeding female or male patient 
a. Female patients of child-bearing potential who are abstinent (if this is complete 
abstinence, as their preferred and usual lifestyle) or in a same-sex relationship (as part 
of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a 
same-sex relationship without sexual relationships with the opposite sex. 
b. Total abstinence is defined as refraining from intercourse during the entirety of the study 
and for at least 1 week following the last dose of investigational product. Periodic 
abstinence such as calendar, ovulation, symptothermal, post-ovulation methods and 
withdrawal are not acceptable methods of contraception. 
c. Otherwise, female patients of childbearing potential must agree to use 2 effective 
methods of contraception, where at least 1 form is highly effective, for the entirety of the 
study and for at least 1 week following the last dose of investigational product. 
d. The following contraception methods are considered acceptable (the patient should 
choose 2, and 1 must be highly effective [defined as less than 1% failure rate per year 
when used consistently and correctly]): 
• 
Highly effective birth control methods: 
o Combined (estrogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation: oral, intravaginal, or transdermal 
o Progestogen- only containing hormonal contraception associated with inhibition 
of ovulation: oral, intravaginal, or transdermal 
o intrauterine device (IUD)/intrauterine hormone-releasing system (IUS) 
o vasectomized male (with appropriate post-vasectomy documentation of the 
absence of sperm in the ejaculate). 
• 
Effective birth control methods: 
o Male or female condom with spermicide. It should be noted that the use of male 
and female condoms as a double barrier method is not considered acceptable 
due to the high failure rate when these methods are combined. 
• 
Diaphragm with spermicide 
• 
Cervical sponge 
• 
Cervical cap with spermicide 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
10 
Note: When local guidelines concerning highly effective or effective methods of birth 
control differ from the above, the local guidelines must be followed. 
 
Female patients of non‒child-bearing potential are not required to use birth control and 
they are defined as: 
• 
Women who are infertile due to surgical sterilization (hysterectomy, bilateral 
oophorectomy, or tubal ligation) 
• 
Post-menopausal – defined either as 
o A woman at least 50 years of age with an intact uterus, not on  hormone 
therapy, who has either 
• 
Cessation of menses for at least 1 year 
• 
At least 6 months of spontaneous menorrhea with follicle-stimulating 
hormone >40 mIU/mL 
o Women aged 55 years or older who are not on hormone therapy, and who 
have had at least 6 months of spontaneous amenorrhea 
o Women aged 55 years or older who have a diagnosis of menopause 
 
Informed Consent 
5. Must read and understand the informed consent approved by the institutional review board 
(IRB)/ethics review board (ERB) governing the site and provide written informed consent. 
2.a 
Exclusion Criteria  
Patients will be excluded from study enrollment if they meet any of the following criteria: 
 
Disease Characteristics 
6. Have  rapidly  progressive  disease, as determined by the treating ophthalmologist, that 
places the patient at an unacceptable risk for participating in the study 
 
Medical Conditions 
7. Have had any major surgery within 8 weeks prior to screening or will require major surgery 
during the study that, in the opinion of the investigator would pose an unacceptable risk to 
the patient. 
8. Have experienced any of the following within 12 weeks of screening: VTE (DVT/pulmonary 
embolism [PE]), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New 
York Heart Association Stage III/IV heart failure. 
9. Have a history of recurrent (≥ 2) VTE (DVT/PE). 
10. Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, 
endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious 
and/or unstable illness that in the opinion of the investigator, could constitute an 
unacceptable risk when taking investigational product or interfere with the interpretation of 
data. 
11. Have a history of lymphoproliferative disease; have signs or symptoms suggestive of 
possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; have 
active primary or recurrent malignant disease; or have been in remission from clinically 
significant malignancy for <5 years prior to randomization. 
 
The following may be exempted: 
a. Patients with cervical carcinoma in situ that has been resected with no evidence of 
recurrence or metastatic disease for at least 3 years may participate in the study. 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
11 
b. Patients with basal cell or squamous epithelial skin cancers that have been completely 
resected with no evidence of recurrence for at least 3 years may participate in the study. 
 
12. Have a current or recent (<4 weeks prior to randomization) clinically serious viral, bacterial, 
fungal, or parasitic infection or any other active or recent infection that in the opinion of the 
investigator, would pose an unacceptable risk to the patient if participating in the study. 
 
Note: For example, a recent viral upper respiratory tract infection or uncomplicated urinary 
tract infection need not be considered clinically serious. 
 
13. Have symptomatic herpes simplex at the time of randomization 
14. Have had symptomatic herpes zoster infection within 12 weeks prior to randomization 
15. Have a history of disseminated/complicated herpes zoster (for example, ophthalmic zoster 
or CNS involvement). 
16. Have a positive test for hepatitis B virus (HBV) defined as: 
a. positive for hepatitis B surface antigen (HBsAg), or 
b. positive for hepatitis B core antibody (HBcAb) and positive for hepatitis B virus 
deoxyribonucleic acid (HBV DNA) 
 
Note: Patients who are HBcAb-positive and HBV DNA-negative may be enrolled in the 
study but will require additional HBV DNA monitoring during the study. 
 
17. Have hepatitis C virus (HCV) infection (hepatitis C antibody-positive and HCV ribonucleic 
acid [RNA]-positive). 
 
Note: Patients who have documented anti-HCV treatment for a past HCV infection AND are 
HCV RNA-negative may be enrolled in the study. 
 
18. Have evidence of HIV infection and/or positive HIV antibodies 
19. Have had household contact with a person with active TB and did not receive appropriate 
and documented prophylaxis for TB 
20. Have evidence of active TB or latent TB 
a. Have evidence of active TB, defined in this study as the following: 
o Positive purified protein derivative (PPD) test (≥5 mm induration between 
approximately 2 and 3 days after application, regardless of vaccination history), 
medical history, clinical features, and abnormal chest x-ray at screening 
o QuantiFERON®-TB Gold test or T-SPOT®.TB test (as available and if compliant with 
local TB guidelines) may be used instead of the PPD test. Patients are excluded 
from the study if the test is not negative and there is clinical evidence of active TB 
 
Exception: patients with a history of active TB who have documented evidence of 
appropriate treatment, have no history of re-exposure since their treatment was completed, 
have no clinical features of active TB, and have a screening chest x-ray with no evidence of 
active TB may be enrolled if other entry criteria met. Such patients would not be required to 
undergo the protocol-specific TB testing for PPD, QuantiFERON®-TB Gold test, or T-
SPOT®.TB test but must have a chest x-ray at screening (i.e., chest imaging performed 
within the past 6 months will not be accepted). 
 
b. Have evidence of untreated/inadequately or inappropriately treated latent TB, defined in 
this study as the following: 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
12 
o Positive PPD test, no clinical features consistent with active TB, and a chest x-ray 
with no evidence of active TB at screening; or 
o If the PPD test is positive and the patient has no medical history or chest x-ray 
findings consistent with active TB, the patient may have a QuantiFERON®-TB Gold 
test or T-SPOT®.TB test (as available and if compliant with local TB guidelines).  If 
the test results are not negative, the patient will be considered to have latent TB (for 
purposes of this study); or 
o QuantiFERON®-TB Gold test or T- SPOT®.TB test (as available and if compliant 
with local TB guidelines) may be used instead of the PPD test. If the test results are 
positive, the patient will be considered to have latent TB. If the test is not negative, 
the test may be repeated once within approximately 2 weeks of the initial value. If the 
repeat test results are again not negative, the patient will be considered to have 
latent TB (for purposes of this study). 
 
Exception: Patients who have evidence of latent TB may be enrolled if he or she completes 
at least 4 weeks of appropriate treatment prior to randomization and agrees to complete the 
remainder of treatment while in the trial. 
Exception: Patients with a history of latent TB who have documented evidence of 
appropriate treatment, have no history of re-exposure since their treatment was completed, 
have no clinical features of active TB, and have a screening chest x-ray with no evidence of 
active TB may be enrolled if other entry criteria met. Such patients would not be required to 
undergo the protocol-specific TB testing for PPD, QuantiFERON®-TB Gold test, or T-
SPOT®.TB test but must have a chest x-ray at screening (i.e., chest imaging performed 
within the past 6 months will not be accepted). 
 
21. Have received any of the following medications: 
a. Cyclophosphamide (or any other cytotoxic agent) within 4 weeks of screening. 
b. Rituximab or any other B cell depleting therapies within 12 weeks of screening. 
22. Have been treated with probenecid that cannot be discontinued for the duration of the study. 
23. Have been exposed to a live vaccine within 12 weeks of randomization or are expected to 
need/receive a live vaccine during the course of the study (with the exception of herpes 
zoster vaccination). 
 
Note: All patients who have not previously received the herpes zoster vaccine by screening 
will be encouraged (per local guidelines) to do so prior to randomization; vaccination with 
live herpes zoster vaccine must occur >4 weeks prior to randomization and start of 
investigational product. Patients will not be randomized if they were exposed to a live herpes 
zoster vaccination within 4 weeks of planned randomization. Investigators should review the 
vaccination status of their patients and follow the local guidelines for vaccination of patients 
≥18 years of age with nonlive vaccines intended to prevent infectious disease prior to 
entering   patients into the study. 
 
24. Are currently enrolled in or have discontinued within 4 weeks of screening from any other 
clinical trial involving an investigational product or nonapproved use of a drug or device or 
any other type of medical research judged not to be scientifically or medically compatible 
with this study. 
25. Have screening laboratory test values, including thyroid-stimulating hormone (TSH), outside 
the reference range for the population that, in the opinion of the investigator, pose an 
unacceptable risk for the patient’s participation in the study. Patients who are receiving 
thyroxine as replacement therapy may participate in the study, provided stable therapy has 
been administered for ≥12 weeks and TSH is within the laboratory’s reference range. 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
13 
Patients who have TSH marginally outside the laboratory’s normal reference range and are 
receiving stable thyroxine replacement therapy may participate if the treating physician has 
documented that the thyroxine replacement therapy is adequate for the patient 
26. Have any of the following specific abnormalities on screening laboratory tests from the 
central or local laboratory 
a. ALT or AST >2 x upper limits of normal (ULN) 
b. alkaline phosphatase (ALP) ≥2 x ULN 
c. total bilirubin ≥1.5 x ULN 
d. hemoglobin <10 g/dL (100.0 g/L) 
e. total white blood cell count <3000 cells/μL (<3.00 x 103/μL or <3.00 billion/L) 
f. neutropenia (absolute neutrophil count [ANC] <1500 cells/µL) (<1.50 x 103/µL or 
<1.50 billion/L) 
g. lymphopenia (lymphocyte count <1000 cells/μL) (<1.00 x 103/μL or <1.00 bilion/L) 
h. thrombocytopenia (platelets <100,000 cells/μL) (<100 x 103/μL or <100 billion/L) 
i. 
eGFR <60 mL/min/1.73 m2  (Bedside Schwartz formula 2009) 
In the case of any of the aforementioned laboratory abnormalities, the tests may be 
repeated once during screening, and values resulting from repeat testing may be accepted 
for enrollment eligibility if they meet the eligibility criterion 
 
Other Exclusions 
27. Are largely or wholly incapacitated permitting little or no self-care, such as being bedridden 
or confined to wheelchair 
28. In the opinion of the investigator, are at an unacceptable risk for participating in the study 
29. Have donated more than a single unit of blood within 4 weeks prior to screening or intend to 
donate blood during the course of the study 
30. Have a history of intravenous drug abuse, other illicit drug abuse, or chronic alcohol abuse 
within the 2 years prior to screening or are concurrently using, or expected to use during the 
study, illicit drugs (including marijuana) 
 
Note: Patients who are prescribed medical marijuana by a physician are not excluded from 
the study. 
 
31. Are unable or unwilling to make themselves available for the duration of the study and/or are 
unwilling to follow study restrictions/procedures 
32. Are investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological 
or legally adopted 
2.b 
Ethical Considerations  
There are no currently FDA-approved medications for the treatment of ocular mucous 
membrane pemphigoid. 
 
We   have   designed   this   study   to   compare   baricitinib   monotherapy   with anti-
proliferative monotherapy. One ethical concern is that subjects enrolled in this study may be 
placed at risk of ocular damage due to uncontrolled disease if baricitinib is not efficacious. We 
believe the design of this study minimizes those risks for the following five reasons. (1) In most 
cases, ocular MMP is a slowly progressive disease with accumulation of ocular damage 
occurring over years. (2) The study  design  measures  disease  activity  at  an  early  time  point  
that  limits  accumulation  of irreversible  scarring  while  still  being  able  to  measure  changes  
in  disease  activity. (3)  Subjects with residual disease activity at week 9 will be transitioned to 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
14 
combination therapy with baricitinib and anti-proliferatives  as  rescue  therapy. (4)  Subjects  
with  rapidly  progressive  disease (as determined by the treating ophthalmologist) are excluded 
from the study. (5) We will perform an interim  analysis  after  half  the  patients  have  reached  
the  primary  endpoint  in  order  to  evaluate whether to terminate the trial early due to lack of 
efficacy. As a result, this study design reduces the risk of lack of efficacy to study participants. 
 
While a placebo-controlled study can provide the strongest evidence for efficacy, use of a 
placebo arm  (either  alone  or in  addition  to anti-proliferatives)  creates  ethical  concerns  for  
patients  with active disease. In contrast, our study design provides active therapy for all 
participants. In order to be able to enroll as many patients as possible, this proposal offers 
several anti-proliferatives for standard of care so that patients will not be prescribed a 
previously-failed therapy. 
2.c 
Subject Recruitment Plans and Consent Process 
Patients seen in the clinical offices of the Department of Ophthalmology & Visual Sciences and 
the Division of Rheumatology at Washington University will be consented in a private room 
within the clinical office.  
 
2.d 
Randomization Method and Blinding 
Subjects will be randomized using sealed envelopes in a 1:1 ratio to either baricitinib 4mg daily 
or to standard of care with an anti-proliferative, such as methotrexate, azathioprine, or 
mycophenolate. Small block sizes will be used. The Biostatistics core in the Department of 
Ophthalmology and Visual Sciences will prepare a randomization schedule. A duplicate 
randomization schedule will be retained in a REDCap HIPAA-compliant database. 
 
For participants randomized to the anti-proliferative group, the anti-proliferative they receive 
(methotrexate, azathioprine, or mycophenolate) will be decided based on comorbidities and 
treatment history. If no contraindications, we typically use methotrexate first, mycophenolate 
second, and azathioprine third; however this will be decided by the physician. 
 
2.e 
Risks and Benefits 
As with other immunosuppressive treatments to control autoimmune diseases, the patients will 
be at increased risk of serious infections, which may result in hospitalization and/or fatality. 
Infections are more likely to develop in patients receiving concomitant immunosuppressive 
agents (e.g., methotrexate, corticosteroids), which is only applicable during rescue therapy. 
Other risks include upper respiratory infection (16%), nausea (3%), herpes zoster infection 
(1%), and laboratory abnormalities (1-2%). Laboratory abnormalities include: 
• 
Hematologic toxicity, including lymphopenia, anemia, and neutropenia 
• 
ALT and AST elevation 
 
Lymphoma and other malignancies have been reported in patients receiving baricitinib. 
 
Tuberculosis (pulmonary or extrapulmonary) has been reported in patients receiving baricitinib. 
Standard laboratory screening is performed in all patients to assess for latent / chronic infection, 
such as TB.  
 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
15 
Thrombosis, including deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial 
thrombosis have been observed in patients receiving baricitinib; these may be serious and life-
threatening. Patients at increased risk of DVT/PE are excluded from the trial. 
 
There is a risk associated with lack of efficacy. Patients will have the opportunity to switch to 
rescue therapy with combined baritinib and anti-proliferative treatment. 
 
Potential benefits include improved control of the ocular inflammatory disease and prevention of 
permanent vision loss. The participants may also derive satisfaction from contributing to medical 
research. 
2.f 
Early Withdrawal of Subjects  
Participants may withdraw at any time from the study. They will be asked to undergo an Early 
Exit Visit. The Early Exit Visit will include the following procedures:  
- 
If prior to week 9, the visit will include medication collection, ocular exam, photography, 
patient survey, adverse event collection, and biospecimen collection. 
- 
If after week 9 during open label extension, the visit will include adverse event collection.  
2.g 
When and How to Withdraw Subjects  
Participants will contact the researcher if they wish to withdraw. 
2.h 
Data Collection and Follow-up for Withdrawn Subjects  
Participants who withdraw will no longer be followed in the study. 
2.i 
Temporary Discontinuation of Therapy 
i 
Indications for temporary discontinuation of therapy 
In some circumstances, patients may need to temporarily interrupt treatment as a result of AEs 
or abnormal laboratory values that may have an unclear relationship to baricitinib. 
 
Abnormal laboratory findings: 
1. ANC < 1 x 10^9 cells/L 
2. ALC < 0.5 x 10^9 cells/L 
3. Hb < 8 g/dL 
4. ALT or AST > 5x ULN 
 
Clinical events: 
5. Symptomatic Herpes Zoster 
6. Infection that, in the opinion of the investigator, merits baricitinib being interrupted 
ii 
Monitoring after temporary discontinuation of therapy 
Abnormal laboratory findings: 
Serial CBC and/or CMP will be obtained every 1 to 4 weeks at the discretion of the treating 
physician. 
 
Clinical events: 
Patients will be monitored as clinically indicated until resolution of infection and the completion 
of antivirals or antibiotics. 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
16 
iii 
Reinitiation of therapy 
Abnormal laboratory findings: 
1. Return of ANC to > 1 x 10^9 cells/L 
2. Return of ALC to > 0.5 x 10^9 cells/L 
3. Return of Hb to > 8 g/dL 
4. Return of ALT and AST to < 2x ULN and baricitinib is considered not to be the cause of the 
enzyme elevation 
 
Clinical events: 
5. All skin lesions have crusted and are resolving 
6. Resolution of infection that, in the opinion of the treating physician, merits baricitinib being 
restarted. 
2.j 
Permanent Discontinuation of Therapy 
i 
Indications for cessation of therapy 
1. The patient or the patient’s designee requests to discontinue investigational product. 
2. Abnormal laboratory findings: 
a. ALT or AST >8 x ULN 
b. ALT or AST >5 x ULN for more than 2 weeks after temporary interruption of 
investigational product 
c. ALT or AST >3 x ULN and total bilirubin level (TBL) >2 x ULN or international normalized 
ratio (INR) >1.5 
d. ALT or AST >3 x ULN with the appearance of fatigue, nausea, vomiting, right 
upper-quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) 
e. ALP >3 x ULN that is deemed to be of liver origin and drug-related 
f. ALP >2.5 x ULN and TBL >2 x ULN 
g. ALP >2.5 x ULN with the appearance of fatigue, nausea, vomiting, right upper-quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%) 
h. White blood cell count <1000 cells/µL (1.00 x 103/µL or 1.00 billion/L) 
i. 
ANC <500 cells/µL (0.50 x 103/µL or 0.50 billion/L) 
j. 
Lymphocyte count <200 cells/µL (0.20 x 103/µL or 0.20 billion/L) 
k. Hemoglobin <6.5 g/dL (<65.0 g/L) 
 
Note:  Temporary interruption rules must be followed where applicable.  For laboratory 
values that meet permanent discontinuation thresholds, investigational product should be 
discontinued.  However, if in the opinion of the treating physician, the laboratory 
abnormality is due to intercurrent illness such as cholelithiasis or another identified factor, 
laboratory tests may be repeated.  Only when the laboratory value meets resumption 
thresholds following the resolution of the intercurrent illness or other identified factor may 
the treating physician restart baricitinib after consultation with the independent medical 
monitor, Dr. Musiek. 
 
3. Clinical events: 
a. Pregnancy 
b. Malignancy 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
17 
c. HBV DNA detected with a value above limit of quantitation 
d. Development of a VTE (DVT/PE) during the study  
ii 
Monitoring after treatment cessation 
Patients who permanently discontinue baricitinib treatment will remain in the study and be 
followed to obtain safety data. 
2.k 
Adjustment of therapy 
Indications for adjustment of therapy 
1. Patients who develop impaired renal clearance (GFR 40 to 60 mL/minute/1.73 m2). 
Adjustment therapy  
1. The dose of baricitinib will be held or reduced (e.g. from 4mg to 1 or 2mg daily) at the 
discretion of the treating physician.  
D3 Study Drug  
3.a 
Description  
Baricitinib is a small molecule that inhibits Janus kinase (JAK). Specifically, it inhibits JAK1 and 
to a lesser extent JAK2. This inhibition occurs downstream of multiple pro-inflammatory 
cytokines, such as IL-2, IL-6, & IFN, and explains the anti-inflammatory effects of baricitinib. It 
has demonstrated clinical efficacy in rheumatoid arthritis. 
3.b 
Treatment Regimen  
Study Drug: Baricitinib will be taken as 4mg daily orally. 
 
Antiproliferatives: The target dose of methotrexate, azathioprine and mycophenolate will be 
20mg weekly, 2mg/kg daily,  and  1g  twice  daily, respectively, all in oral formulation.  Dosing  
of anti-proliferatives may  be  adjusted (e.g. decreased) based on toxicity and tolerability. 
3.c 
Method for Assigning Subjects to Treatment Groups  
Subjects will be assigned to treatment groups by the research coordinator using sealed 
envelopes in a 1:1 provided by the Biostatistics  core  in the Department  of Ophthalmology  and  
Visual  Sciences. A  duplicate randomization schedule will be retained in a REDCap HIPAA-
compliant database. 
3.d 
Preparation and Administration of Study Drug  
Preparation is not required. Baricitinib will be provided by Eli Lilly, the manufacturer of the drug. 
The research team will provide pre-packaged bottles to the patients. Antiproliferatives will be 
prepared by the pharmacy. Patients will self-administer baricitinib and antiproliferatives. 
3.e 
Subject Compliance Monitoring  
Patients will be asked to present empty medication bottles to demonstrate adherence during 
regular clinical follow-up. 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
18 
3.f 
Prior and Concomitant Therapy  
During Masked Trial Period 
Due to the need to maximize the number of eligible patients to meet recruitment goals, no type 
of prior therapy is prohibited. Prior therapy, however, must be discontinued upon study 
enrollment. Concurrent systemic immunotherapy is not allowed until the patient requires rescue 
therapy at week 9.  
 
Patients will have eye lubricant and topical antibiotics to use prior to visits associated with 
weeks 1, 5, and 9.  
 
Ocular surface optimization will be achieved with lubricating drops (daytime), lubricating 
ointment (night time), and antibiotic drops for the 7 days preceding visits 2 (week 1), 3 (week 5), 
and 4 (week 9). Recommended formulation (and dosing) is preservative-free artificial tears (1 
drop, four times per day), lubricating ophthalmic ointment (applied at bedtime), and moxifloxacin 
0.5% (1 drop, four times per day); however, the selection and dosing of therapy will ultimately 
be up to the treating ophthalmologist. 
 
Patients will undergo trichiatic eye lash removal (epilation) at week 0 and subsequently as 
needed by the treating ophthalmologist. 
 
During Open Label Extension and Rescue Therapy 
Combination therapy with baricitinib and anti-proliferatives (methotrexate, azathioprine, and 
mycophenolate) is allowed if the patient requires rescue therapy at week 9. 
 
Patients will undergo trichiatic eye lash removal (epilation) as needed by the treating 
ophthalmologist. 
3.g 
Packaging  
Packaging will be provided by Eli Lilly, the manufacturer of the drug. 
 
Packaging of antiproliferatives will be performed by the pharmacy. 
3.h 
Masking of Study Drug  
This is a single masked study where the evaluator of disease activity is masked to treatment. 
3.i 
Receiving, Storage, Dispensing and Return  
The baricitinib will be shipped to the PI who will store the drug in a locked room at room 
temperature. An established and validated local temperature management system with 
temperature logs will be used to record the storage temperature. The research team will 
dispense baricitinib to the patients during their clinical visit. 
 
Antiproliferatives will be dispensed to the patients from the pharmacy. 
 
 
 
 
 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
19 
E Study Procedures  
 
E1 Screening for Eligibility 
Clinicians and research coordinators on the research team will identify potential participants via 
a computerized search for relevant diagnoses and via clinical identification of ocular MMP 
during patient encounters. The clinician and/or research coordinator will discuss the study with 
potential participants during the patient encounter. Consent will be signed prior to drug 
administration. 
E2 Measurements 
• 
Visual Acuity is measured with the ETDRS chart. 
• 
Intraocular pressure will be measured by Goldmann Applanation Tonometer. 
• 
Disease activity (of the eye) is measured by ophthalmology exam.* 
• 
Fibrosis is measured by ophthalmology exam.* 
• 
Patient Reported Outcomes are measured by the NEI VFQ-25) and Skindex-16. 
• 
Biospecimens to be collected at blood, tears, and impression cytology of the conjunctival 
surface. 
o Blood will be collected in 4 purple top tubes and processed in the Yokoyama Lab 
o Tears wil be collected with a glass micropipette and processed in the Yokoyama 
Lab 
o Impression cytology will be collected with filter paper and processed in the Huang 
Lab or Yokoyama Lab. 
 
* Drs. Huang and Margolis are ophthalomogists with subspecialty training in corneal disease. 
These two investigators will perform all slit-lamp examinations. 
E3 Schedule of Measurements 
Schedule of measurements are listed in Table 1. 
E4 Initial Visit (Week 0; screening) 
• 
Informed consent 
• 
Inclusion/Exclusion criteria verification 
• 
Medical history and Demographics 
• 
Concomitant Medication collection 
o Dose of medications used to treat increased intraocular pressure 
o Dose of topical and/or systemic medications 
• 
Ophthalmology data 
o Visual Acuity 
o Intraocular pressure 
o Disease activity assessment 
o Fibrosis assessment 
o Corneal Disease 
o Extraocular Manifestations 
• 
Provide Subject Study Handout 
• 
Provide Drug Package Insert 
• 
Randomization 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
20 
• 
Laboratory blood draw 
• 
Chest Xray if prior history of TB (laboratory or clinical evidence) 
o To be obtained during visit or prior to week 1 visit 
• 
Undergo trichiatic eye lash removal (epilation); this may also be done subsequently 
throughout their participation as needed by the treating ophthalmologist 
 
Patients will have eye lubricant and topical antibiotics to use prior to visits associated with 
weeks 1, 5, and 9. 
 
At the time of consent, participants will be asked in the consent form if they agree to allow data 
and biospecimens to be stored for use in future studies.  
E5 Baseline Visit (Week 1) 
• 
Concomitant Medication collection 
o Dose of medications used to treat increased intraocular pressure 
o Dose of topical and/or systemic medications 
• 
Ophthalmology data 
o Visual Acuity 
o Intraocular pressure 
o Disease activity assessment 
o Fibrosis assessment 
o Corneal Disease 
o Extraocular Manifestations 
• 
Conjunctiva photography 
• 
Patient Survey / Patient Reported Outcomes 
• 
Collection of Biospecimens (blood, tears, and impression cytology) 
• 
Dispense Study Drug 
E6 Subsequent visit (Week 5) 
• 
Concomitant Medication collection 
o Dose of medications used to treat increased intraocular pressure 
o Dose of topical and/or systemic medications 
• 
Ophthalmology data 
o Visual Acuity 
o Intraocular pressure 
o Disease activity assessment 
o Fibrosis assessment 
o Corneal Disease 
o Extraocular Manifestations 
• 
Conjunctiva photography 
• 
Patient Survey / Patient Reported Outcomes 
• 
Adverse Event Collection 
• 
Dispense Study Drug 
E7 Subsequent visit (Week 9) 
• 
Concomitant Medication collection 
o Dose of medications used to treat increased intraocular pressure 
o Dose of topical and/or systemic medications 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
21 
• 
Ophthalmology data 
o Visual Acuity 
o Intraocular pressure 
o Disease activity assessment 
o Fibrosis assessment 
o Corneal Disease 
o Extraocular Manifestations 
• 
Conjunctiva photography 
• 
Patient Survey / Patient Reported Outcomes 
• 
Adverse Event Collection 
• 
Collection of Biospecimens (blood, tears, and impression cytology) 
• 
Dispense Study Drug for participants continuing on open label extension treated with 
study drug 
E8 Open-Label Extension 
• 
Research visits will occur in conjunction with clincal visits as per standard of care 
• 
Adverse Event Collection 
• 
Dispense Study Drug for participants continuing on open label extension treated with 
study drug 
• 
Patients will undergo trichiatic eye lash removal (epilation) as needed by the treating 
ophthalmologist. 
 
Participants who take part in the Open-Label Extension will be asked if they agree to optional 
biospecimen collection that would occur approximately every 6 months. The first collection will 
occur approximately 6 months after they start the trial, and would occur approximately every 6 
months after that. The exact timing of when the biospecimens are collected would be dependent 
on when participants have standard of care visits. 
 
E9 E-mail and Text Message Communication 
Participants may be contacted through e-mail or text message to facilitate execution of the 
study. For example, participants may be contacted regarding scheduling appointments, 
appointment reminders, need to contact the study team / treating physician about labs or 
imaging. 
E10 Safety and Adverse Events  
10.a Safety and Compliance Monitoring 
Safety and compliance monitoring will be performed by research coordinator at weeks 5 and 9 
and in conjunction with clinical visits during open label extension. 
 
Patients will return empty bottles of baricitinib to demonstrate compliance. 
10.b Medical Monitoring  
i 
Data Safety Monitoring  
The independent medical monitor Dr. Amy Musiek will review the study data every 6 months 
until study completion.  

 
 
 
 
 
 
______________________________________________________________________________________ 
 
22 
ii 
Hepatitis B Virus DNA Monitoring 
Hepatitis B virus DNA testing will be performed in enrolled patients who tested positive for 
HBcAb at screening. 
 
Patients who are HBcAb-positive and HBV DNA-negative (undetectable) at Visit 1 will require 
HBV DNA monitoring every 3 months and at the patient’s last visit, regardless of their hepatitis 
B surface antibody (HBsAb) status. The every 3 month monitoring would only be for those who 
choose to also take part in the open-label extension portion. 
 
The following actions should be taken in response to HBV DNA test results 
• 
If a single result is obtained with a value “below limit of quantitation,” the test should be 
repeated within approximately 2 weeks. 
• 
If the repeat test result is “target not detected,” monitoring may resume according to the 
study schedule. 
• 
If the patient has 2 or more test results with a value “below limit of quantitation” during 
the study, HBV DNA testing should be performed approximately once per month for the 
remainder of the study and referral to a hepatologist is recommended. 
• 
If a result is obtained with a value above limit of quantitation at any time during the study, 
the patient will be permanently discontinued from investigational product and should be 
referred to a hepatology specialist immediately 
 
10.c Definitions of Adverse Events (AEs) 
An adverse event is any untoward medical occurrence (including an abnormal laboratory 
finding), in a patient or clinical trial subject administered a medicinal product temporally 
associated with the use of a study agent(s), whether or not related to the study agent(s), 
occurring as soon as the patient has signed the informed consent form and at any time during 
the study. All adverse events always must be recorded in the CRF. AEs also include an 
undesirable medical condition occurring, even if no study treatment has been administered 
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect 
10.d Definition of Serious Adverse Events (SAEs) 
An SAE is any AE from this study that results in one of the following outcomes: 
• 
death 
• 
initial or prolonged inpatient hospitalization 
• 
a life-threatening experience (that is, immediate risk of dying) 
• 
persistent or significant disability/incapacity 
• 
congenital anomaly/birth defect 
• 
important medical events that may not be immediately life-threatening or result in death 
or hospitalization but may jeopardize the patient or may require intervention to prevent 
one of the other outcomes listed in the definition above. 
10.e Pregnancy 
Pregnancy (during maternal or paternal exposure to investigational product) does not meet the 
definition of an AE. However, to fulfill regulatory requirements, any pregnancy should be 
reported following the SAE process to collect data on the outcome for both mother and fetus. 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
23 
10.f Classification of Events 
i 
Relationship 
For all AEs, the investigator will assess the causal relationship between baricitinib and the AE 
using his/her clinical expertise and judgment according to the following algorithm that best fits 
the circumstances of the AE: 
 
The investigator will interpret and document whether or not an AE has a reasonable possibility 
of being related to baricitinib, taking into account the disease, concomitant treatment or 
pathologies.  
 
A “reasonable possibility” means that there is a cause and effect relationship between baricitinib 
and the AE. The investigator answers yes/no when making this assessment. 
 
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the study. 
ii 
Severity 
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting. A copy of the 
CTCAE version 4.0 can be downloaded from the CTEP website: 
http://evs.nci.nih.gov/ftp1/CTCAE/About.html 
iii 
Expectedness 
Unanticipated problems are defined as: 
• 
Unexpected (in terms of nature, severity, or frequency) given (a) the research 
procedures that are described in the protocol-related documents, such as the IRB-
approved research protocol and informed consent document; and (b) the characteristics 
of the subject population being studied. 
• 
Related or possibly related to participation in the research (“possibly related” means 
there is a reasonable possibility that the incident, experience, or outcome may have 
been caused by the procedures involved in the research). 
• 
Suggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized. 
10.g Data Collection Procedures for Adverse Events 
Patients will be interviewed about adverse events during scheduled follow-up for the duration of 
the study. Laboratory studies will be reviewed at each visit per protocol for the first 9 weeks and 
then per standard of care for the open label extension. 
 
10.h Reporting Procedures 
Information on serious adverse event reporting will be provided in letter of agreement with Eli 
Lilly. 
 
The PI is required to promptly notify the IRB of the following events: 
• 
Any unanticipated problems involving risks to participants or others which occur at any 
Washington University or Barnes Jewish Hospital institution 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
24 
• 
Any unanticipated problems that impacts participants or the conduct of the study. 
• 
Noncompliance with federal regulations or the requirements or determinations of the 
IRB. 
• 
Receipt of new information that may impact the willingness of participants to participate 
or continue participation in the research study. 
10.i 
Serious Adverse Event Reporting Period 
These events must be reported to the IRB within 10 working days of the occurrence of the event 
or notification to the PI of the event. The death of a research participant that qualifies as a 
reportable event should be reported within 1 working day of the occurrence of the event or 
notification to the PI of the event 
10.j 
Post-study Adverse Event 
Post-study adverse events will be identified through routine follow-up of these patients with 
chronic diseases by their treating rheumatologist for 60 days after study completion. 
E11 Study Outcome Measurements and Ascertainment 
1. Visual acuity will be measured by Early Treatment Diabetic Retinopathy Study chart 
2. Intraocular Pressure will be measured by tonometry 
3. The primary endpoint (disease activity) will be a calculated score as described above 
based on ophthalmologic exam by a cornea specialist 
4. Fibrosis will be based on Tauber grade from ophthalmologic exam by a cornea specialist 
5. Corneal involvement will be based on ophthalmologic exam by a cornea specialist 
6. Therapeutic response of extra-ocular manifestations will be measured via a skin exam 
and calculated based on Table 2 
7. Conjunctiva photography will be obtained using a slit-lamp-mounted camera 
8. Patient Reported Outcomes (PROs) such as the National Eye Institute Visual Function 
Questionnaire-25 (NEI VFQ-25) and Skindex-16 will be collected by the research 
coordinator via patient survey 
 
F Statistical Plan  
 
F1  Sample Size Determination and Power 
The study is mainly designed as a pilot study to estimate the treatment response and variability 
of ocular MMP to baricitinib for induction of low disease activity. The sample size of 20 (10 per 
group) was selected to collect data to determine if further studies of baricitinib would be justified.  
The study was not powered to provide sufficient power for a formal test of therapeutic effect, but 
to detect a signal for efficacy.  The rationale for n of 20 assumes a two-sided alpha error rate of 
0.10 rather than 0.05 and statistical power of 0.4, 0.7, and 0.9 for effect sizes ranging from 0.6, 
1.0, and 1.3 respectively. Effect size is the ratio of the mean difference between active vs. 
placebo groups divided by their common standard deviation. An effect size of 0.2 would be 
considered a small therapeutic  effect,  0.5  a  medium  effect,  and  0.8  a  large  effect (20). 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
25 
F2 Interim Monitoring and Early Stopping 
An interim analysis will be conducted after 10 patients have been assessed for disease activity 
at week 9.  The review will be conducted by the biostatistician Dr. Gordon, the independent 
medical monitor, Dr. Musiek, and consultant, Dr. Strand.  Collaborators, including Drs. Paley, 
Huang, and Margolis, will be masked to the interim results, except in the event of early 
termination of the study.  No formal statistical test will be conducted at the time of the interim 
analysis. We will determine if further recruitment is justified based on all data, in particular effect 
size, from 10 patients. If the standard care group is superior to the baricitinib group, then a 
decision to terminate the study will be considered.  In this manner, the number of patients 
exposed to inferior experimental treatment is minimized (21).  A formal interim analysis is not 
justified given the low statistical power of the study and the uncertainties of parameters needed 
to estimate statistical power.   
F3  Analysis Plan 
The statistical analysis plan focuses on the detection of a signal for efficacy-an estimate of 
effect size and variance of efficacy outcomes.  The primary outcome measure will be disease 
activity determined by the sum of inflammation scores of each eye.   
F4 Statistical Methods  
The primary hypothesis will be analyzed using data from both eyes of each patient in a nested, 
repeated measures analysis of variance model with randomization as a fixed effect.  Data will 
be transformed if needed to meet assumptions of parametric modeling.      
F5  Missing Outcome Data 
Patients with missing outcome data in the primary endpoints will be censored for the initial 
analysis for efficacy. 
F6  Unmasking Procedures  
The data will be unmasked at the conclusion of the trial.  Drs.  Paley,  Huang, and Margolis, will 
be masked to the interim results, except in the event of early termination of the study. 
 
G Data Handling and Record Keeping  
 
G1 Confidentiality and Security 
Consents will be scanned into the medical record. Original hard copies of consents will be 
secured under two keys and two locks in a locked file-cabinet within a locked office. Prospective 
clinical data will be collected during the study and entered into RedCap (a HIPAA-compliant and 
password-protected database.) All aspects of the medical record will be analyzed including age, 
sex, office visit data, phone number, MRN, chief complaint, history of present illness, past 
medical and surgical history, past ocular history, medications, allergies, exam findings, studies 
including clinical images, ultrasound, and radiographic studies, laboratory and pathology data, 
diagnosis, assessment and plan as well as clinical outcomes. Data sent to Eli Lilly will be de-
identified. 
 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
26 
Biospecimens will be de-identified and labeled with study number, tissue isolate, and date of 
collection. Blood and tear samples are stored in a locked freezer in the Yokoyama Lab. 
Impression cytology samples will be stored in the Huang Lab.  
G2 Training  
All researchers have undergone confidentiality and ethical training through Washington 
University. 
G3 Records Retention 
Electronic records of patient treatment will be stored in the electronic medical record (EMR) and 
in REDCap. Consents will be scanned into the EMR. These will be saved for the lifespan of the 
EMR and REDCap. Hard copies of records (e.g. consents) will be kept in compliance with the 
University policies. 
 
H Study Monitoring, Auditing, and Inspecting  
 
H1 Study Monitoring Plan  
The investigators will meet every 4 weeks to review study data to detect early evidence of 
unanticipated harm to subjects. The review will focus on safety data including but not limited to 
serious adverse drug events, drug exposure, laboratory test results, and vital signs 
measurements as well as the rate of treatment failure. 
H2 Auditing and Inspecting  
2.a 
Audits 
In order to guarantee that the conduct of the study is in accordance with good clinical practice 
and national laws, audits may be performed at the study sites to be carried out by an 
independent auditor. In addition, for-cause audits may be scheduled. The investigators agree to 
give the auditor access to all relevant documents for review. 
2.b 
Inspections 
Inspections of the study sites may be performed by the local or regulatory authorities at any time 
during or after completion of the study. The investigators agree to give the inspectors access to 
all relevant documents for review.  
I Study Administration 
 
I1 
Organization and Participating Centers 
Principal Investigator: Michael Paley MD, PhD 
 
See IRB submission for complete list of participating clinicians and research coordinators. 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
27 
 
This is a single-site study at Washington University. 
 
I2 
Funding Source and Conflicts of Interest 
This trial is sponsored by Eli Lilly. The research team members do not currently have any 
financial conflicts of interest. The PI will maintain records during the trial regarding whether any 
research team members have financial conflicts of interest. 
I3 
Subject Stipends or Payments  
Subjects will receive stipends of $50 for each study visit, 4 in total. 
I4 
 Study Timetable 
Planned Start Date: November 1st, 2020 
Planned Completion Date: December 31st, 2022 
 
J Publication Plan  
 
The results of this study will be submitted for publication to a peer-reviewed journal. 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
28 
 
K  Attachments  
 
K1  Tables  
Table 1 
 
Measurement 
Timepoints 
Grader 
1ary: Disease activity 
Weeks 0, 1, 5, & 9 
Drs. Huang and Margolis* 
2ary: Visual Acuity 
Weeks 0, 1, 5, & 9 
Research Coordinator 
2ary: Fibrosis 
Weeks 0, 1, 5, & 9 
Drs. Huang and Margolis* 
2ary: Corneal Disease 
Weeks 0, 1, 5, & 9 
Drs. Huang and Margolis* 
2ary: Extraocular Manifestations 
Weeks 0, 1, 5, & 9 
Dr. Paley 
Intraocular Pressure 
Weeks 0, 1, 5, & 9 
Research Coordinator 
Exploratory: Photographs 
Weeks 1, 5, & 9 
Research Coordinator 
Exploratory: Biospecimens / Biomarkers 
Weeks 1 and 9 
Dr. Paley 
Exploratory: PROs (NEI & Skindex) 
Weeks 1, 5, & 9 
Research Coordinator 
 
 
 
Laboratory monitoring (CBC, CMP, Lipid) 
Weeks 0 & 9 
Dr. Paley 
Infection monitoring (T.spot & HBV/HCV) 
Week 0 
Dr. Paley 
 
 
 
Adverse Event Collection 
Weeks 1, 5 & 9 
Research Coordinator 
Concurrent Medication Collection 
Weeks 0, 1, 5, & 9 
Research Coordinator 
Medical History and Demographics 
Week 0 
Research Coordinator 
 
*Drs. Huang and Margolis are ophthalomogists with subspecialty training in corneal disease. 
These two investigators will perform all slit-lamp examinations.  

 
 
 
 
 
 
______________________________________________________________________________________ 
 
29 
Table 2: Adapted scoring from Munyangango et al. for grading of extraocular disease: 
Surface 
Score 
Definition of Activity 
Score 
Definition of Damage 
Gingiva a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nongingival 
segments b 
0 
No Erythema 
0 
No erythema 
1 
Erythema in 1 segment with no erosion 
2 
Scar(s) in 1 segment 
2 
Erythema in 1 or 2 segments or erosion(s) in 1 
segment 
4 
Scars in 2 segments or atrophy in 1 
segment 
3 
Erythema in 3 or 4 segments or erosions in 2 
segments 
6 
Scars in 3 segments, atrophy in 2 
segments 
or 
synechia(e) 
in 
1 
segment 
4 
Erythema in 5 or 6 segments or erosions in 3 
segments 
8 
Scars in 4 segments, atrophy in 3 
segments 
or 
synechiae 
in 
2 
segments 
5 
Generalized 
ulcerative 
‘desquamative 
gingivitis’ 
10 
Scars in 5 segments, atrophy in 4 or 
5 segments or synechiae in > 2 
segments 
1 
Erythema in 1 segment with no erosion 
 
 
2 
Erythema in 2 segments or erosion(s) in < 
25% of 1 segment 
 
 
3 
Erythema in 3 segments, erosions in 25–49% 
of 1 segment or erosions in < 25% of 2 
segments 
 
 
4 
Erosions in 50–75% of 1 segment, erosions in 
25–49% of 2 segments or erosions in < 25% 
of 3 segments 
 
 
 
 
 
 
 
Nose 
5 
Erosions in > 75% of 1 segment, erosions in 
50–75% of 2 segments, erosions in 25–49% of 
3 segments or erosions in < 25% of 4 
segments 
 
 
0 
No Erythema 
 
   
1 
Erythema with no erosion 
   
 
2 
Erosions present 
 
   
 
 
Genital  
Mucous 
Membrane c 
 
   
 
 
2 
Erythema in 1 segment with no erosion 
2 
Scar(s) in 1 segment 
4 
Erythema in 1 or 2 segments or erosion(s) in 1 
segment 
4 
Scars in 2 segments 
6 
Erythema in 3 or 4 segments or erosions in 2 
segments 
6 
Scars in 3–5 segments 
8 
Erythema in 5 segments or erosions in 3 
segments 
8 
Synechiae in 1–5 segments 
 
 
10 
Erosions in > 3 segments 
10 
Stenosis 
 
 
 
 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
30 
Surface 
Score 
Definition of Activity 
Score 
Definition of Damage 
 
 
Anal  
Mucous 
Membrane d 
 
 
 
 
2 
Erythema in 1 segment 
2 
Scar in 1 segment 
4 
Erythema in 2 segments or 1 erosive segment 
4 
Scars in 2 segments 
6 
Erythema in 3 or 4 segments or 2 erosive 
segments 
6 
Scars in 3 or 4 segments 
8 
Erythema in 5–7 segments or 3 erosive 
segments 
8 
Scars in 5 segments 
 
10 
≥ 3 erosive segments 
10 
Stenosis 
 
 
a Gingiva is divided into six segments: upper and lower anterior segments, defined as extending 
in front of the incisors and the canines, and left and right posterior segments (×4).  
b Oral non-gingival segments include buccal mucosae (×2), soft palate, hard palate, tongue and 
floor, lips.   
c Genital mucous membrane includes five segments: clitoris–vestibule, labia majora (×2)/minora 
(×2) for women, meatus, glans (two halves), prepuce (two halves) for men.  
d Anal area includes seven segments: perianal quadrants (×4), anal canal, posterior line, 
perineal segment.  
K2 Informed consent documents 
See separate informed consent document in IRB submission. 
K3 Questionnaires or surveys 
Patients will be asked to complete the National Eye Institute Visual Function Questionnaire-25 
(NEI VFQ-25) and Skindex-16 at baseline and on return visits while on therapy. 
 
L References 
1. 
J. Dacosta, Ocular cicatricial pemphigoid masquerading as chronic conjunctivitis: a case 
report. Clin Ophthalmol 6, 2093-2095 (2012). 
2. 
S. Sarny, M. Hucke, Y. El-Shabrawi, Treatment of Mucous Membrane Pemphigoid With 
Janus Kinase Inhibitor Baricitinib. JAMA Ophthalmol 136, 1420-1422 (2018). 
3. 
A. M. Suelves, T. Z. Zhao, S. S. Siddique, C. S. Foster, Profile of local interleukin 
expression in a cohort of ocular cicatricial pemphigoid patients. Invest Ophthalmol Vis 
Sci 53, 8112-8117 (2012). 
4. 
V. P. Saw et al., Conjunctival interleukin-13 expression in mucous membrane 
pemphigoid and functional effects of interleukin-13 on conjunctival fibroblasts in vitro. 
Am J Pathol 175, 2406-2415 (2009). 
5. 
G. Kaplanski, V. Marin, F. Montero-Julian, A. Mantovani, C. Farnarier, IL-6: a regulator 
of the transition from neutrophil to monocyte recruitment during inflammation. Trends 
Immunol 24, 25-29 (2003). 
6. 
O. Dienz, M. Rincon, The effects of IL-6 on CD4 T cell responses. Clin Immunol 130, 27-
33 (2009). 

 
 
 
 
 
 
______________________________________________________________________________________ 
 
31 
7. 
R. Yang et al., IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-
21-producing B helper CD8+ T cells. J Exp Med 213, 2281-2291 (2016). 
8. 
B. Li, L. L. Jones, T. L. Geiger, IL-6 Promotes T Cell Proliferation and Expansion under 
Inflammatory Conditions in Association with Low-Level RORgammat Expression. J 
Immunol 201, 2934-2946 (2018). 
9. 
G. Jego, R. Bataille, C. Pellat-Deceunynck, Interleukin-6 is a growth factor for 
nonmalignant human plasmablasts. Blood 97, 1817-1822 (2001). 
10. 
S. Li et al., Autoantibodies From Single Circulating Plasmablasts React With Citrullinated 
Antigens and Porphyromonas gingivalis in Rheumatoid Arthritis. Arthritis Rheumatol 68, 
614-626 (2016). 
11. 
P. Stathopoulos, A. Kumar, R. J. Nowak, K. C. O'Connor, Autoantibody-producing 
plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia 
gravis. JCI Insight 2,  (2017). 
12. 
E. M. Munyangango et al., Oral cyclophosphamide without corticosteroids to treat 
mucous membrane pemphigoid. Br J Dermatol 168, 381-390 (2013). 
13. 
W. Stevenson et al., Effects of topical Janus kinase inhibition on ocular surface 
inflammation and immunity. Cornea 33, 177-183 (2014). 
14. 
T. Sakimoto, A. Ishimori, Anti-inflammatory effect of topical administration of tofacitinib 
on corneal inflammation. Experimental Eye Research 145, 110-117 (2016). 
15. 
S. H. Liew et al., Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: 
results from a phase 1/2 trial. Ophthalmology 119, 1328-1335 (2012). 
16. 
J. F. Huang et al., Immunomodulatory effect of the topical ophthalmic Janus kinase 
inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology 119, 
e43-50 (2012). 
17. 
P. C. Taylor et al., Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N 
Engl J Med 376, 652-662 (2017). 
18. 
E. C. Keystone et al., Safety and efficacy of baricitinib at 24 weeks in patients with 
rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum 
Dis 74, 333-340 (2015). 
19. 
H. S. Ong, J. F. Setterfield, D. C. Minassian, J. K. Dart, G. Mucous Membrane 
Pemphigoid Study, Mucous Membrane Pemphigoid with Ocular Involvement: The 
Clinical Phenotype and Its Relationship to Direct Immunofluorescence Findings. 
Ophthalmology 125, 496-504 (2018). 
20. 
J. Cohen, Statistical power analysis for the behavioral sciences.  (Academic Press, New 
York, ed. Rev., 1977), pp. xv, 474 p. 
21. 
S. Wieand, G. Schroeder, J. R. O'Fallon, Stopping when the experimental regimen does 
not appear to help. Stat Med 13, 1453-1458 (1994).